XERF · Industry Trends · A Physician's Perspective

What buying XERF
made me notice about Taiwan.
And why I now watch that market for what comes next.

This article really starts with a purchase, not a theory.

When we decided to bring XERF into Skin Trek, what impressed me was not a sales pitch. It was the machine itself. The design felt thoughtful. The dual-frequency concept was interesting. The cooling made sense. The treatment philosophy matched how I already think about monopolar RF. Even the consumable model felt much less punitive than what many clinics have become accustomed to.

And because I had spent so many years with Thermage before that, the contrast was hard to ignore.

I left Taiwan with a very particular picture of the aesthetic device market in my head. American platforms defined the premium end. Korean systems were present, but they were rarely the machines people spoke about with the same reverence. Looking back now, that picture feels outdated.

"The interesting question is no longer whether Korean devices can compete with American ones. It is why so many of the devices physicians are excited about now are coming from Korea in the first place."

The market in Taiwan really did change

There is data behind that impression. In its 2023 annual report, Dynamic Medical Technologies — a Taiwanese medical-aesthetic distributor — wrote that Taiwan was no longer sourcing predominantly from leading European and US brands and estimated that Korean-made aesthetic energy devices had surpassed 50% of the local market. That is the company's estimate rather than an independent market census, so I would not treat 50% as an exact national count. But the direction is difficult to miss. Read the annual report.

Korea itself has become a serious device-development ecosystem. A 2025 Swiss Business Hub Korea report found that from 2019 to 2023, Korean production of non-invasive cosmetic medical devices grew at a 17% compound annual rate, while exports grew at 24%. Classys reported that overseas Ultraformer MPT installations passed 5,000 units by the end of 2025 and overseas Volnewmer installations passed 2,300. Korea market data · Classys 2025 annual report.

What XERF crystallised for me about Korean design

XERF is not the whole argument. But it was the trigger that made the argument impossible for me to ignore.

As I wrote in my separate piece on why we chose XERF over Thermage, what stood out to me was not a flashy promise that one machine would somehow defeat physics. It was that the platform seemed designed around the lived reality of treatment: dual-frequency delivery, controllable cooling, visible feedback, technique flexibility, a large treatment tip and clinic economics that do not feel openly adversarial.

I would be careful saying that Korean R&D is universally better than American R&D. The United States still produces extraordinary technology, fundamental research and published evidence. But in aesthetic energy devices, Korea has become exceptionally good at turning engineering into something a physician actually wants to use all day.

The business model matters as much as the physics

This part is rarely discussed in patient-facing device comparisons, but it matters enormously to clinics.

In my own purchasing experience in Canada, a Thermage treatment tip has been roughly $500–600, often with purchasing programs that require meaningful inventory commitments. The XERF consumable, in my current purchasing experience, is roughly $250 and can be ordered in much smaller quantities.

That difference changes more than gross margin. It changes working capital, inventory risk, promotional flexibility, how easily a clinic can price a treatment, and how rapidly a platform can spread.

Not every Korean manufacturer has a gentle commercial model, and not every North American manufacturer is aggressive. But broadly, many newer Asian manufacturers seem more interested in getting the platform into clinical use first and monetising the installed base at a level the clinic can live with. In a market as competitive as Taiwan, that matters.

Why Taiwan moves so quickly in the first place

One thing that is easy to underestimate from North America is just how compressed Taiwan's aesthetic market is.

SkinDay currently identifies 2,170+ clinics in Taiwan. That is a striking number for a market of roughly 24 million people on a relatively small island. For context, SkinDay currently identifies 8,425+ clinics in Canada, 8,559+ clinics in California and 6,235+ clinics in New York.

That is why I think Taiwan is so useful as a leading-indicator market. The strongest density argument is geographic concentration, not clinics per capita. In fact, using SkinDay's current counts, Taiwan has fewer listed aesthetic clinics per million residents than Canada, California or New York State. What is different is how tightly those clinics and consumers are packed together. In Taiwan, consumers often have many credible clinics within a short distance. Prices are easier to compare. New treatments become visible quickly. And when one clinic invests in a new technology or service, nearby clinics notice very quickly because they are competing for the same patients.

North America works differently. Canada is vast. The United States is even more fragmented. California may have more clinics than Taiwan in absolute terms, but those clinics are spread across a far larger geography and a much more distributed set of local markets. A device can become popular in Los Angeles while remaining almost irrelevant in San Francisco, Toronto, Vancouver or New York. In Taiwan, competitive signals travel faster because the market is physically and commercially tighter.

That creates a kind of market compression:

"New technology enters the market. Early adopters move first. Consumers notice quickly. Competitors react quickly. And because so much of this happens in a compact geography, adoption pressure builds faster than it does in a market spread across a continent."

Taiwan is a high-speed clinical market

One reason I watch Taiwan is how quickly a new device can move from “interesting” to visible, and then from visible to normal.

Wontech's Oligio is a useful example. The company says it received Taiwan TFDA approval in August 2022, sold its first 50 systems there within three months, and passed 120 systems roughly eight months after launch. Wontech's Taiwan update.

That is not just a distributor selling machines. Once enough clinics have the device, physicians compare techniques, patients start recognising the name, treatment pricing becomes visible, social media fills with before-and-afters and competitors are forced to respond. Adoption feeds awareness, and awareness feeds more adoption.

Taiwan's Classys distributor tells a similar story of sustained Korean penetration: it became Classys' exclusive Taiwan distributor in 2013, launched Ultraformer II in 2014, Ultraformer III in 2018, Ultraformer MPT in 2023 and Volnewmer in 2024, and now reports relationships with more than 500 medical institutions. Ugintech company history.

So is North America really three to five years behind?

Sometimes. But not in the simple way I first described it.

The regulatory data are a useful reality check. Oligio received US FDA clearance in October 2022 — almost the same period it entered Taiwan. Volnewmer reached Taiwan, Canada and the United States in 2024. Those examples do not show a three-to-five-year regulatory lag at all.

Ultraformer MPT is the opposite. Classys lists Taiwan in its 2023 rollout and Canada in 2024, while its 2024 annual report showed the US launch planned for 2027. That is a four-year gap between Taiwan and the planned US market entry. Classys regulatory rollout.

So I would refine my own thesis this way:

"North America is not automatically three to five years behind in approval. It can be several years behind in what becomes normal clinical behaviour, consumer awareness and the economic expectations clinics place on device companies."

That is much harder to measure than an FDA date, but it is what I have felt practising in both markets.

Why the direction of influence may have reversed

Fifteen years ago, Taiwan watched the United States for the next premium device. Increasingly, I think North American aesthetics is watching Asia — sometimes without fully realising it.

The influence does not arrive as a direct copy. It comes through Korean devices gaining FDA and Health Canada clearance, Asian treatment concepts becoming familiar on social media, physicians travelling for training, distributors bringing successful platforms west, and patients asking for treatments they first encountered in Seoul, Taipei, Hong Kong or mainland China.

The important part is not whether every trend travels west. Many do not. The important part is that Taiwan gives us a high-volume preview of which technologies physicians keep using after the launch event is over.

What I am watching now

I am paying less attention to which company has the biggest booth or the best-known logo, and more attention to a few practical signals:

This does not mean buy Korean

Country of origin is a poor way to choose a medical device.

There are excellent American platforms, excellent Korean platforms, mediocre products from both, and machines that are brilliantly marketed but clinically uninteresting. Evidence still matters. Safety still matters. Service still matters. And above all, the operator still matters.

What has changed for me is the assumption.

I no longer assume that the American device is the innovation and the Korean device is the alternative. I evaluate the engineering first, the clinical logic second, the economics third, and the logo last.

XERF did not make me abandon that discipline. It reminded me why that discipline matters.

Sources & notes

Accurate as of September 2026. Device approvals, launch timing, pricing and market share change; this page is dated rather than left to age quietly.